Surgical and Oncological Treatments in Gastric Cancer: A Retrospective Analysis of 1-Year Survival and Its Clinical Implications

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035827

Enrollment

152

Registered

2025-02-10

Start date

2023-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C16

Interventions

Group 1: Patients undergoing curative gastrectomy for gastric cancer, combined with perioperative oncological therapies and oncological parameters

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Underwent curative gastrectomy (R0 resection) Availability of complete clinical data (e.g., age, sex, BMI, TNM classification, lymph node -status, tumor regression grade) Documentation of oncological therapy (neoadjuvant, adjuvant, perioperative) Availability of follow-up data (1-year survival)

Exclusion criteria

Exclusion criteria: Patients with missing follow-up within one year after surgery

Design outcomes

Primary

Measure	Time frame
The 1-year survival after curative gastrectomy for gastric cancer	—

Secondary

Measure	Time frame
Prognostic factors for 1-year survival, including oncological treatment modalities, tumor regression grade (Becker classification), lymph node status (N0 vs. non-N0), and surgical approach (robotic vs. open).	—

Countries

Germany

Contacts

Public ContactMazen Juratli

Universitätsklinikum Münster (UKM)Klinik für Allgemein-, Viszeral- und Transplantationschirurgie

mazen.juratli@ukmuenster.de+49 251 8351493

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026